← Research library

Rumalon in knee osteoarthritis: blinded first year and two-year extension

Randomized study in people · 1987

What was studied
50 people with knee osteoarthritis at Hospital General, Mexico City. Twenty-five were randomized to each group in year one.
Main finding
The first, double-blind year found no significant advantage over placebo in 50 randomized patients. Both groups received Rumalon in the two-year extension.

Reported findings and study design

One year of parallel, double-blind, randomized treatment versus placebo, followed by two open years of active treatment in both groups.

Population or model 50 people with knee osteoarthritis at Hospital General, Mexico City. Twenty-five were randomized to each group in year one.

Dose, route and schedule

Rumalon 2 mL intramuscularly three times a week during eight-week courses. Three courses in year one. Both groups received active treatment in years two and three, two courses per year.

Protocol source ↗ · Original indexed abstract and opening page of the journal article scan.

Results · Original indexed abstract and opening page of the journal article scan.
MeasureResultComparison, timing and statistics
End of the blinded comparisonNo statistically significant between-group differencesYear 1 · 25 randomized per arm
Night and rest painReported improvement favored two years of active exposure over one yearYear 2
Radiographic severity16% improved, 74% unchanged, 10% worsenedYear 3, after both groups received active drug
Symptoms in the extensionRest and walking pain and morning stiffness improved overall. Night pain and pain while standing or climbing stairs showed no significant overall improvement.Year 3

Year-three imaging was assessed blind. The extension had no concurrent placebo group.

Source for these results ↗ · Reviewed 2026-11-15

Study limitations and source details

Study limitations

  • Anti-inflammatory drugs and physiotherapy were allowed. Comparisons after year one reflect groups with different durations of active treatment. The accessible abstract gives no adverse-event counts.

Source details

Original indexed abstract and opening page of the journal article scan.

Sources checked

Citation

Randomized trialEnglish abstract

G. Katona. Rumalon in knee osteoarthritis: blinded first year and two-year extension Current Medical Research and Opinion. 1987;10(9):625–633.

Study source ↗ · DOI 10.1185/03007998709112416 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards